Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation

NCT00809250 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Myelodysplastic Syndrome-Refractory Anemia With Excess Blasts

Interventions

BIOLOGICAL: GM-K562/leukemia cell vaccine

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]
[object Object]